Modafinil: a second look. Confirmed efficacy in narcolepsy.


     Related Videos
2006 NMC Summer Conference Second Life
24. The Second Law of Thermodynamics (cont.) and Entropy
Infidelity A 90-second lecture
What the Second Generation Holds
Calculus Second Derivative Test

     Related Hubpages

    Field: Medicine  DOWNLOAD  BOOKMARK REPORT
    •  Doc. Url:    Embed Code: 

    • PubMed  status
      (0) (0 Votes)
      		Views: ()   Date: (1999-11-11)   Pages: ()

    • Author:  

    • Abstract:  (1) Modafinil, a psychostimulant, has been available in France for the treatment of narcolepsy and idiopathic hypersomnia since 1994. (2) The initial clinical file was inadequate to judge its possible clinical value. (3) In narcolepsy three new short-term clinical trials have compared modafinil with a placebo (nearly 500 patients treated with modafinil). (4) These trials show that the effects of modafinil on daytime drowsiness are only moderate (average reduction of one unwanted sleep episode a day) but are subjectively better than those of a placebo. In all, 84% of patients preferred the modafinil period to the placebo period during a cross-over trial. In contrast, modafinil does not improve cataplexy. (5) No new trials have been done in idiopathic hypersomnia. (6) The effects of modafinil persist for at least four months according to a double-blind placebo-controlled trial. (7) The safety profile of modafinil appears to be similar to that of non amphetamine psychostimulants. (8) There is currently no evidence of dependence leading to withdrawal symptoms after abrupt treatment cessation, or of a risk of abuse.

         Related Documents

           Related Groups

             Related Science News

               More on Sciencestage

                 Answers

                 News
            • Grant aimed at improving schizophrenia treatment
              (SACRAMENTO, Calif.) - Michael Minzenberg, a UC Davis psychiatry researcher, has been awarded a prestigious three-year, $200,000 seed grant from the Dana Foundation to study the brains of patients being treated for schizophrenia
            • Grant will fund study of cognition and schizophrenia
              SACRAMENTO — Michael Minzenberg, a UC Davis psychiatry researcher, has been awarded a prestigious three-year, $200,000 seed grant from the Dana Foundation to study the brains of patients being treated for schizophrenia to determine how additional treatment to improve cognition interacts with antipsychotic medication.
            • Bullets to beat the enemy within
              ARMY leaders in various countries have trialled compounds that can keep soldiers awake and alert — or send them to sleep
            • Regeneron reports total revenues of $123.0M for fourth quarter 2011
              Regeneron Pharmaceuticals, Inc. today announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.
            • Is it true that someone with Sleep Apnea is more likely to have a motor vehicle accident than ...
              Dear Dr. Rosenberg, Is it true that someone with Sleep Apnea is more likely to have a motor vehicle accident than others? My son has Sleep Apnea and refuses to get treated. He and his wife just had their first child, so I am concerned. Should I be? Yes, you should. The incidence of MVA (Motor Vehicle Accidents) in men with Sleep Apnea is three times the risk of others. Interestingly, it is less ...
            • How dementia drugs could be used by the military
              Army leaders in various countries have trialled compounds that can keep soldiers awake and alert – or send them to sleep Drugs that reduce anxiety, tiredness and memory loss – all associated with the treatment of dementia – could be used "off-label" as cognitive enhancers by military personnel, according to a Royal Society report . While caffeine and nicotine are used routinely to reduce fatigue ...
            • Neuroprotection - Drugs, Markets and Companies
              NEW YORK, Feb. 1, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Neuroprotection - Drugs, Markets and Companies http://www.reportlinker.com/p0203546/Neuroprotection---Drugs-Markets-and-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_MedicationThis ...
            • We must be science's masters, not at its mercy | John Harris
              Recent advances in neuroscience, such as memory manipulation, create compelling ethical dilemmas This week it was reported that soldiers could potentially, in the near future, have their minds plugged directly into weapons systems , and have their learning boosted by neural stimulation. The Royal Society's Brain Waves project on new directions in neuroscience gives us much to reflect on and ...
            • Immunome Launches $1.5 Million Offering - cbl
              By Bill Murphy WYNNEWOOD, Pa. -- Immunome Inc. has raised $145,000, or nearly a tenth of a $1.50 mil...

                 Related on Wikipedia




























             

            Powered free by PHPmotion